Reports >
Life Sciences
>
Psoriasis Therapeutics Market Report
Psoriasis Therapeutics Market Report
First published: 11 October 2024 | Last updated: 25 May 2026 | Report Code: psoriasis-therapeutics
Psoriasis Therapeutics Market — USD 10.5 billion in 2023, Growing to USD 20.64B by 2033 at 6.8% CAGR
This report provides an in-depth analysis of the Psoriasis Therapeutics market, covering industry trends, market size, segmentation, and regional insights from 2023 to 2033. It offers valuable data that can aid in strategic planning and forecasting.
Key Takeaways
- Global market expands from $10.50 Billion in 2023 to $20.64 Billion in 2033 at a 6.8% CAGR.
- North America is largest regional market, while no single fastest-growing region is stated because regional CAGR differences remain within 0.15 percentage points.
- Europe grows from $2.64 Billion in 2023 to $5.20 Billion in 2033, reflecting expanded therapeutic options.
- Asia Pacific rises from $2.03 Billion to $4.00 Billion during 2023–2033 amid broader treatment adoption.
- Key industry players include AbbVie Inc., Amgen Inc., Johnson & Johnson., and Novartis AG.
Psoriasis Therapeutics Market Report — Executive Summary
North America remains largest market by forecast-period value, while no single fastest-growing region is stated because top regional growth rates are separated by less than 0.15 percentage points. The Psoriasis Therapeutics Market Report analyzes a market that expands from $10.50 Billion in 2023 to $20.64 Billion in 2033, reflecting a 6.8% CAGR over the 2023 to 2033 forecast period. Growth is supported by innovation in biologics, expanding systemic therapies, and improved access through diverse distribution channels. Regional dynamics vary: North America leads in absolute market value, while Europe and Asia Pacific show notable increases. The report covers segmentation by therapy type (Biologics, Topical Agents, Systemic Therapy), routes of administration, patient demographics, and distribution. Competitive coverage highlights established firms such as AbbVie Inc., Amgen Inc., Johnson & Johnson., and Novartis AG. Methodology combines primary expert interviews with secondary company reports, triangulated and validated internally to present actionable insights for stakeholders considering product development, market entry, or partnership strategies.
Key Growth Drivers
- Increased adoption of biologic therapies expanding treatment options and market uptake.
- Rising healthcare investment and improved access via hospital and retail pharmacies plus e-commerce.
- Ongoing R&D and regulatory approvals introducing targeted and systemic treatment innovations.
- Greater use of personalized approaches and digital health tools improving disease management.
- Expanding prevalence awareness and diagnostic capabilities supporting earlier treatment initiation.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $10.50 Billion |
| CAGR (2023-2033) | 6.8% |
| 2033 Market Size | $20.64 Billion |
| Top Companies | AbbVie Inc., Amgen Inc., Johnson & Johnson., Novartis AG. |
| Published Date | 11 October 2024 |
| Last Modified Date | 25 May 2026 |
Psoriasis Therapeutics Market Overview
Customize Psoriasis Therapeutics Market Report market research report
- ✔ Get in-depth analysis of Psoriasis Therapeutics market size, growth, and forecasts.
- ✔ Understand Psoriasis Therapeutics's regional dynamics and industry-specific trends.
- ✔ Identify potential applications, end-user demand, and growth segments in Psoriasis Therapeutics
What is the Market Size & CAGR of Psoriasis Therapeutics Market Report market in 2023?
Psoriasis Therapeutics Industry Analysis
Psoriasis Therapeutics Market Segmentation and Scope
Tell us your focus area and get a customized research report.
Psoriasis Therapeutics Market Report Market Analysis Report by Region
Europe Psoriasis Therapeutics Market Report:
Europe grows from $2.64 Billion in 2023 to $5.2 Billion in 2033. Expanded access to novel therapies, regulatory approvals, and broader clinical adoption of systemic and biologic treatments are key regional drivers.Asia Pacific Psoriasis Therapeutics Market Report:
Asia Pacific grows from $2.03 Billion in 2023 to $4 Billion in 2033. Growth is supported by improving healthcare infrastructure, increased diagnosis rates, and greater availability of advanced therapeutic options.North America Psoriasis Therapeutics Market Report:
North America is largest regional market, rising from $3.83 Billion in 2023 to $7.53 Billion in 2033. This region's scale reflects uptake of advanced biologics, established distribution networks, and significant healthcare spending that support higher absolute market values.South America Psoriasis Therapeutics Market Report:
Latin America grows from $0.9 Billion in 2023 to $1.77 Billion in 2033. Market development is influenced by improving treatment availability and growing awareness of therapeutic choices.Middle East & Africa Psoriasis Therapeutics Market Report:
Middle East and Africa grows from $1.09 Billion in 2023 to $2.14 Billion in 2033. Regional progress is driven by gradual improvements in healthcare access and the introduction of newer treatment modalities.Tell us your focus area and get a customized research report.
Research Methodology
Psoriasis Therapeutics Market Analysis By Therapy Type
In 2023, the Biologics segment holds a market share of 66.99% with a value of $7.03 billion, projected to reach $13.82 billion by 2033. Topical agents follow with a market share of 26.59%, and Systemic therapy accounts for 6.42%. These segments highlight the preference for biologic treatments due to their targeted action and efficacy.
Psoriasis Therapeutics Market Analysis By Route Of Administration
The Oral route accounts for 66.99% of the market in 2023, valued at $7.03 billion, and is projected to grow significantly to $13.82 billion by 2033. This is followed by Topical and Injectable routes which account for 26.59% and 6.42% respectively, indicating a strong preference for convenient oral and topical therapies due to ease of administration.
Psoriasis Therapeutics Market Analysis By Patient Type
The Adults segment dominates the market with a size of $8.49 billion in 2023, projected to grow to $16.68 billion by 2033. This segment makes up 80.83% of the total market share, while the Children segment, valued at $2.01 billion, is expected to increase to $3.96 billion, capturing 19.17% of the market share. Strategies targeting adults are likely essential for capturing the largest patient population.
Psoriasis Therapeutics Market Analysis By Distribution Channel
Hospital Pharmacies lead with a market size of $8.49 billion in 2023, capturing 80.83% of the market share and forecasted to increase to $16.68 billion by 2033. Retail Pharmacies and E-commerce contribute a smaller share, valued at $2.01 billion (19.17% market share) in 2023 with projected growth to $3.96 billion, highlighting the importance of hospital settings in psoriasis management.
Psoriasis Therapeutics Market Trends and Future Forecast
Tell us your focus area and get a customized research report.
Global Market Leaders and Top Companies in Psoriasis Therapeutics Industry
AbbVie Inc.:
AbbVie is a leading biopharmaceutical company known for its extensive research and development in psoriasis treatment, particularly through its immunology portfolio including Humira and Rinvoq.Amgen Inc.:
Amgen is a biopharmaceutical company that focuses on innovative therapies in dermatology, having made significant strides in developing biologics for psoriasis management.Johnson & Johnson.:
Johnson & Johnson is a well-established healthcare company that provides a range of dermatological products, including those specifically designed for psoriasis, such as Tremfya.Novartis AG.:
Novartis is a global healthcare company recognized for its advancements in psoriasis therapies, including Cosentyx, which targets interleukin-17.We're grateful to work with incredible clients.
FAQs
What is the market size of the psoriasis therapeutics market in 2023?
The market size in 2023 is $10.50 Billion according to the report's base-year data.
How big will the psoriasis therapeutics market be by 2033?
The projected market value for 2033 is $20.64 Billion as stated for the forecast end year.
What is CAGR for the forecast period?
The compound annual growth rate for 2023 to 2033 is 6.8% as provided in the report data.
Is there a single fastest Growing region in the Psoriasis Therapeutics Market Report market?
No single fastest-growing region is stated for the Psoriasis Therapeutics Market Report market because the top regional implied CAGR values are within 0.15 percentage points of each other, making the ranking too close to call reliably.
Who are the top companies operating in this market?
Top companies listed include AbbVie Inc., Amgen Inc., Johnson & Johnson., and Novartis AG.
Why is biologics important to market growth?
Biologics are driving market expansion by offering targeted therapies that increase treatment adoption and support higher-value therapeutic segments.
What patient segments are covered in the report?
The report segments patients by type, specifically listing Adults and Children as the included sub segments.
Which therapy Type segments are detailed?
Therapy-type segmentation includes Biologics, Topical Agents, and Systemic Therapy as specified in the data.
How are distribution channels categorized?
Distribution channels in the report include Hospital Pharmacies and Retail Pharmacies and E-commerce as listed sub segments.
What routes of administration are included?
Routes of administration covered are Oral, Topical, and Injectable according to the provided segment facts.